Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03638115
Other study ID # SEC-BTK-001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 30, 2018
Est. completion date June 30, 2020

Study information

Verified date October 2018
Source Vascuros Medical Pte Ltd
Contact Anthony Lie
Phone +6569096493
Email a.lie@vascuros.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the safety and performance of the VaSecure drug-coated PTA balloon catheter in the treatment of patients with Chronic Limb Threatening Ischemia (CLTI) of the lower limb below the knee (BTK)


Description:

The VaSecure Drug Coated PTA Balloon Catheter is indicated for percutaneous transluminal angioplasty (PTA), after predilatation, of de novo lesions in the peripheral vasculature of the lower limb with reference vessel diameters of 2-4 mm.

The study will include patients with lesions located in the infrapopliteal arteries diagnosed with CLTI of Rutherford categories 3-5. A maximum number of 46 patients will be enrolled in this clinical investigation in 7 sites in Europe and 2 in Singapore.


Recruitment information / eligibility

Status Recruiting
Enrollment 46
Est. completion date June 30, 2020
Est. primary completion date June 1, 2019
Accepts healthy volunteers No
Gender All
Age group 21 Years to 90 Years
Eligibility Inclusion Criteria:

1. Able to provide written informed consent prior to participating in the clinical investigation, e.g. patients are mentally able to understand the aim of the clinical investigation.

2. Has a documented diagnosis of CLTI of Rutherford category 3-5.

3. The target lesion must be de novo.

4. Life expectancy is >1 year, in the investigator's opinion.

5. For women: menopausal or under active birth control.

6. Patient must agree not to participate in any other clinical trial during 12 month follow-up period.

Visual angiographic inclusion criteria

7. Reference vessel(s) diameter is between 2mm-4mm. Each lesion in one or maximum two of the infrapopliteal arteries NOT extending beyond the ankle joint. Target lesion(s) consisting of a single solitary or series of multiple adjacent lesions (all less than 30 mm apart) in a single tibial vessel with a diameter stenosis =70% and a cumulative length of =50 mm to =250 mm. If there are two target lesions they will be separated for =3 cm and will be named from proximal to distal. Target lesion must be a tibial vessel (excluding popliteal artery) branching from popliteal artery.

Exclusion Criteria:

1. Breastfeeding or pregnant woman.

2. Severe concentric calcification, documented by angiography using the COMPLIANCE360-Score (This scoring system takes into account both the arc of calcium (< or > 180º) and percent of lesion length (< or > 50%) as judged by fluoroscopy.) that could not be fully expanded by predilatation balloon and documented by angiography. Valid record up to 30 days before screening.

3. Patients with major amputations that have already been performed or are planned, either on the target leg or on the contralateral side. .

4. History of stroke within 3 months.

5. History of myocardial infarction, thrombolysis or angina within 30 days prior to index procedure.

6. Renal failure or chronic kidney disease with estimated Glomerular Filtration Rate (eGFR) =30 mL/min per 1.73 m2 (or serum creatinine =2.5 mg/dL within 30 days of index procedure or treated with dialysis).

7. Diagnosed active untreated systemic infection or uncontrolled coagulopathy within 14 days prior to index procedure.

8. Co-morbid conditions limiting life expectancy to <12 months.

9. Hemorrhagic diathesis or another disorder such as gastrointestinal ulceration or cerebral circulatory disorders which restrict the use of platelet aggregation inhibitor therapy and anticoagulation therapy.

10. Known allergy to paclitaxel or paclitaxel-related compounds or contrast media that cannot be adequately managed with pre- and post-procedure medication.

11. Is currently participating in an investigational drug or other investigational device study or previously enrolled in this study.

12. Is unlikely to comply with the follow up schedule.

13. Has uncontrolled ulcer wound infection.

14. Is unwilling to comply with a concurrent ulcer wound therapy.

15. Has an allergy to acetylsalicylic acid, prasugrel, ticagrelol, and clopidogrel (Plavix®).

16. Use of atherectomy in proximal vessels or TL. However, the use of scoring/cutting balloons in the TL is allowed.

Angiographic exclusion criteria

17. Lesions that cannot be successfully predilated to achieve a residual stenosis of <50% by visual estimate.

18. Severe dissection post dilatation resulting in a flow limiting lesion.

19. Thrombus in the target vessel documented by angiography.

20. Aneurysm in the target vessel(s).

21. Treatment of the contralateral limb during the same index procedure or within 30 days post-index procedure in order to avoid confounding complications.

Study Design


Intervention

Device:
VaSecure™
Drug Coated PTA Balloon Catheter

Locations

Country Name City State
Belgium Ziekenhuis Oost Limburg Genk
Belgium Regionaal Ziekenhuis Heilig Hart Tienen
Germany Klinikum Hoschsauerland Arnsberg
Germany Universitaetsklinikum Muenster Münster
Germany Regiomed Kliniken Sonneberg Sonneberg
Singapore Changi General Hospital Singapore
Singapore National University Hospital Singapore

Sponsors (2)

Lead Sponsor Collaborator
Vascuros Medical Pte Ltd Novella Clinical

Countries where clinical trial is conducted

Belgium,  Germany,  Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Freedom from a composite endpoint of Major adverse limb event (MALE) and procedure-related mortality. Major adverse limb event is defined as the composite of either major amputation or major re-intervention through 30 days of the index procedure. 30 days
Secondary Procedure success rate Composite of technical success defined as successful vascular access and completion of the endovascular procedure as well as immediate morphological success with <30% residual reduction in diameter as assessed by QVA and Device success defined as exact deployment of the device according to the Instructions For Use (IFU) as documented by suitable imaging means Index procedure or 1 day post index procedure
Secondary Incidence of all Adverse Events (AEs) All AEs will be characterized by severity, relatedness, outcome and treatment 30 days, and 3, 6, 9 and 12 months
Secondary Freedom from major target limb amputation Rates of amputation of the lower limb above 1 cm from the ankle mortice/joint upwards 3, 6, 9 and 12 months
Secondary Freedom from clinically-driven target lesion revascularization (cd-TLR) and target vessel revascularization (TVR) Clinically-driven TLR is defined by core lab confirmation of restenosis =70% in the target lesion with wound persistence, new wounds or re-occurence of ischemic rest pain 3, 6, 9 and 12 months
Secondary Late Lumen Loss (LLL) of the target lesion As measured by QVA 6 months
Secondary Angiographic Restenosis Defined as =70% diameter stenosis on 2-view angiography by visual estimate 6 months
Secondary Angiographic Restenotic Burden Defined as the percentage of length of stenosis/occlusion =70% on 2-view angiography by visual estimate in mm, divided by the total length of the lesion in mm 6 months
Secondary Freedom from occlusion (FFO) without cd-TLR on Duplex ultrasound Defined as presence of flow on colour doppler of the target lesion 3, 6 and 9 months
Secondary Haemodynamic microvascular performance As measured by transcutaneous oxygen (TcpO2) Baseline, 3, 6 and 12 months
Secondary Haemodynamic microvascular performance As measured by Ankle-Brachial-Index (ABI). Baseline, 6 and 12 months
Secondary Wound healing rate Defined as healed or not, if not, improving, stagnant or worsening 30 days, 3, 6, 9 and 12 months.
Secondary Rutherford status Change in Rutherford classification as assessed by the investigator 3, 6, 9 and 12 months
Secondary Clinical Improvement (combined endpoint) in amputation free, cd-TLR free, surviving patients Specified as an improvement shift in the Rutherford classification of one class. 3, 6, 9 and 12 months
Secondary Limb salvage Defined as preservation of a functional foot without the need for a leg prosthesis 6 and 12 months
Secondary Amputation-free survival Defined as composite endpoint of mortality and amputation 6 and 12 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05712395 - The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease N/A
Active, not recruiting NCT04534257 - Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore N/A
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Completed NCT02554266 - Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
Completed NCT03921905 - Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
Not yet recruiting NCT06369350 - Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion Early Phase 1
Recruiting NCT04545268 - Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance N/A
Recruiting NCT02389023 - Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery N/A
Completed NCT02542267 - In-Stent Restenosis Post-Approval Study N/A
Completed NCT02563535 - Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Phase 4
Completed NCT02522884 - Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries N/A
Completed NCT02539940 - Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
Completed NCT02228564 - BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease N/A
Completed NCT02262949 - A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System N/A
Completed NCT02145065 - First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r) N/A
Completed NCT01743872 - Optical Imaging Measurement of Intravascular Solution Efficacy Trial N/A
Recruiting NCT01424020 - Walking Estimated Limitation Calculated by History - Study 2 Phase 4
Active, not recruiting NCT01597453 - NOR-SYS: The Norwegian Stroke in the Young Study N/A